Peptides That Starve Tumors by Blocking New Blood Vessel Growth: A Comprehensive Review

Multiple anti-angiogenic peptides (50 amino acids or shorter) derived from endogenous proteins like thrombospondin, collagens, chemokines, and growth factors have shown promise in preclinical cancer models and some have reached clinical trials. These peptides work by blocking the formation of new blood vessels that tumors need to grow. Various protein modification strategies — including D-amino acid substitution and non-natural amino acid incorporation — have been used to improve their stability and potency. Computational tools and bioinformatics approaches are accelerating the discovery and optimization of new anti-angiogenic peptide candidates.

Comprehensive review surveying published preclinical and clinical data on anti-angiogenic peptides of 50 amino acids or fewer. The authors catalogued peptide sources, receptor targets, modification strategies, and technological advances in peptide discovery including computational and bioinformatics tools.

Tumors cannot grow beyond a few millimeters without recruiting new blood vessels (angiogenesis). Blocking this process with peptides offers a targeted cancer treatment with low toxicity and high specificity compared to conventional chemotherapy. This review catalogs the diverse landscape of anti-angiogenic peptides, showing that the body already produces proteins containing these vessel-blocking fragments — researchers just needed to identify and optimize them.

Anti-angiogenic therapy was one of the most exciting concepts in cancer treatment when bevacizumab (Avastin) was approved in 2004. While the reality has been more nuanced than the initial hype, the approach remains an important part of cancer treatment. Peptide-based anti-angiogenic agents offer potential advantages over antibodies — they're smaller, cheaper to produce, and can penetrate tumors more easily. This review captures the state of the field at a pivotal moment and catalogs the diverse molecular toolkit available for blocking tumor blood vessel formation.

As a 2011 review, it cannot reflect the more recent clinical outcomes of many of the peptides discussed. Anti-angiogenic therapies as a class have had mixed clinical results — preclinical promise has not always translated to clinical success. The review focuses on peptides ≤50 residues, excluding larger anti-angiogenic proteins that may be more clinically advanced.